Dyslipidemia in Renal Transplant Recipients Treated with a Sirolimus and Cyclosporine-Based Immunosuppressive Regimen: Incidence, Risk Factors, Progression, and Prognosis
Resource
TRANSPLANTATION v.76 n.2 pp.375-382
Journal
TRANSPLANTATION
Journal Volume
v.76
Journal Issue
n.2
Pages
375-382
Date Issued
2003
Date
2003
Author(s)
CHUEH, SHIH-CHIEH
Abstract
Background. This retrospective study compared the incidence, severity, and predisposing factors for dyslipidemia among renal transplant patients treated for up to 6 years with a cyclosporine +/- prednisone-based concentration-controlled regimen without (n=118) or with (n=280) ascending exposures to sirolimus. Methods. The diagnosis of dyslipidemia was established when the serum cholesterol value (CHO) was more than 240 mg/dL or serum triglycerides (TG) were more than 200 mg/dL. Generalized estimating equations and mixed- modeling procedures were used for statistical analyses. Results. Hypercholesterolemia was observed in 46% to 80% and hypertriglyceridemia in 43% to 78% of sirolimus-treated patients during the first 6 posttransplantation months. The mean peak serum lipid levels among patients in the sirolimus group (CHO=285.5 mg/dL; TG=322.4 mg /dL) were significantly higher than those in the nonsirolimus group (CHO= 250.2 mg/dL and TG=267.6 mg/dL; both P<0.01). The lipid values, which were persistently elevated during the first posttransplantation year, decreased slowly thereafter but remained significantly higher than the pretransplantation levels beyond 4 years after transplantation. The two forms of hyperlipidemia tended to occur in parallel (Pearson's coefficient of correlation, r=0.5, P<0.001), showing a positive predictive value of 0 .67 and a negative predictive value of 0.65. However, there was no significant difference in the incidence of cardiovascular events within 4 years after transplantation among patients treated with versus without sirolimus. Conclusion. The dyslipidemia associated with sirolimus therapy, albeit persistent, does not seem to represent a major risk factor for the early emergence of cardiovascular complications.
Subjects
RANDOMIZED MULTICENTER
EFFICACY RAPAMYCIN
HYPERLIPIDEMIA
MICROEMULSION
REJECTION